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Short hairpin RNA (shRNA) can be stably expressed in cells to down-modulate gene expression. While retroviral and lentiviral vectors can be
used to deliver shRNAs, the restricted viral titer is the major limitation for efficient gene transfer, which is especially important for cancer gene
therapy. We were interested in using replicating murine leukemia virus (MLV) to enhance the shRNA transfer. Although stem loop structures
could potentially interfere with the retroviral life cycle, we were able to demonstrate that the insertion of shRNA expression cassettes into MLV
did not interfere significantly with viral fitness. The virus was genetically stable and able to silence target gene expression. Our results show that
replicating MLVs are excellent tools for delivering shRNAs efficiently throughout the culture and have the potential to be used for gene function
elucidation or even for cancer gene therapy.
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RNA interference (RNAi) or post-transcriptional gene
silencing mediates resistance to both endogenous parasitic and
exogenous pathogenic nucleic acids, and regulates the expres-
sion of genes. For molecular biologists, RNAi technology
represents one of the most powerful tools ever to be introduced
for the manipulation of gene expression. It provides a simple,
inexpensive and selective method of gene inhibition with high
success rate (Couzin, 2002). In contrast to the cascades that are
activated in cells after exposure to long dsRNA, which lead to
non-specific RNA degradation, RNAi is mediated by short
RNA duplexes not longer than 21 nucleotides (nt) and is a
cellular pathway of gene silencing in a sequence-specific
manner at the mRNA level. Perfectly complementary dsRNA
(short hairpin RNA, shRNA) is chopped up by Dicer, a
ribonuclease-III (RNase III) family member, into small
interfering RNA (siRNA) duplexes 21–23 nt in length with
symmetric 2–3 nt 3′ overhangs. The duplex is then unwound by⁎ Corresponding author. Fax: +49 6103 77 1273.
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doi:10.1016/j.virol.2006.03.014RNA helicase and assembled into the RNA-induced silencing
complex (RISC). It is believed that RISC then directs the siRNA
to the target mRNA, which has the identical sequence. This then
leads to degradation of the target mRNA.
Many groups have reported the use of synthesized
oligonucleotides to induce RNAi in mammalian cells by
transfection. However, this method is transient in nature and
the suppressed phenotype can be lost within several doubling
times, most likely due to the dilution of the siRNA. While this
approach is reliable for short-term studies of gene expression, it
cannot replace knockout mouse models or allow for precise
loss-of-function genetic screens. Plasmids or retroviral vectors
can be used to express shRNA under the control of an RNA
polymerase III (pol III) promoter, such as U6 or H1
(Brummelkamp et al., 2002; Miyagishi and Taira, 2002).
However, these vectors are replication-defective retroviruses
and can only transduce a limited number of cells. This is not
sufficient for the use of RNAi for example cancer therapy and in
vivo applications. Poor delivery rates could be overcome by
insertion of a shRNA expression cassette into a replication-
competent retrovirus, which would distribute the shRNAwhile
replicating in the target cells.
Fig. 1. Identification of functional shRNAs. (A) 293T cells were co-transfected
with pRC-CMV-STAT3-FLAG and the respective pSUPER plasmids carrying
different shRNA variants directed against STAT3, or the unspecific control
carrying the shRNA against EGFR. Cell lysates were analyzed by Western blot
with an antibody against FLAG and equal loading was confirmed by an antibody
directed against β-actin. Lane 1: untransfected 293T cells; Lane 2: STAT3-
FLAG and pSUPER-STAT3-1; Lane 3: STAT3-FLAG and pSUPER-STAT3-2;
Lane 4: STAT3-FLAG and pSUPER-STAT3-3; Lane 5: STAT3-FLAG and
pSUPER-EGFR. The lower panel shows the β-actin bands as a control for equal
loading. (B) 293T cells were either transfected with pLTR-EGFR either alone or
with the shRNA-encoding plasmids in equal amounts, and the EGFR protein
level was determined by Western blot of cell lysates with an antibody against
EGFR. pSUPER-CD4 codes for an shRNA directed against the human CD4-
receptor and was used in this experiment as an unspecific control. Lane 1: pLTR-
EGFR and pSUPER-CD4; Lane 2: 293T cell transfected with the pLTR-EGFR;
Lane 3: pLTR-EGFR and pSUPER-si-EGFR. The lower panel shows β-actin
which served as a loading control.
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against invading viruses, pathogens and nucleic acids in plants
and invertebrates, because they lack the protein-based adaptive
immunity found in higher vertebrates (Tijsterman et al., 2002).
However, recent studies also support the participation of RNA
silencing in viral infection of vertebrates. The influenza viral
protein NS1 (Bucher et al., 2004; Delgadillo et al., 2004) and
vaccinia virus E3L (Li et al., 2004) for example, have negative
regulatory roles in RNA silencing. In addition, RNA silencing
has recently been suggested to control retroviral invasion.
Lecellier et al. (2005) describe a human miRNA that appears to
restrict the replication of primate foamy virus type 1 (PFV-1).
The group also found that PFV-1 encodes a protein called Tas
that seems to suppress the ability of the miRNA to tackle the
virus. In addition, an siRNA precursor sequence with the
capacity to induce RNA silencing has been described in the
human immunodeficiency virus (HIV) genome. Again, the
virus encodes a protein (Tat) able to counteract RNA silencing
(Bennasser et al., 2005). Such proteins are likely to interfere
with the function of an inserted shRNA expression cassette. In
addition, the insertion of a dsRNA stretch into the viral genome
could have adverse effects, keeping in mind that the RNA–
stem–loop structure Tar and the Tat protein of primate
lentiviruses strongly influence their transcription. Murine
leukemia virus (MLV) is a simple retrovirus lacking the
accessory genes common to the more complex lentiviruses
and might lack mechanisms to suppress RNAi. We were
therefore interested to determine whether the insertion of an
expression-cassette for shRNA into a replicating MLV would
interfere with the viral life cycle. Here, we demonstrate that the
insertion did not interfere significantly with viral fitness, and
was genetically stable and functional in silencing target gene
expression. Our results show that replicating MLVs are
excellent tools for the efficient delivery and expression of
shRNAs, have great potential for functional genomics and
might even be suitable for in vivo cancer gene therapy, if
combined with efficient entry targeting.
Results
Identification of functional shRNA
Although the pol III promoter-driven expression of shRNA
has been established as a powerful tool for the specific down-
regulation of genes, the prediction of suitable sequences within
the gene locus still requires functional testing of multiple
shRNAs.
As targets, we used genes that are frequently overexpressed
in tumor cells: the signal transducer and activator of
transcription 3 (STAT3) and the epidermal growth factor
receptor (EGFR). To find an efficient shRNA for these target
genes, we used the mammalian expression vector pSUPER
which drives shRNA synthesis from the pol III H1-RNA gene
promoter (Brummelkamp et al., 2002). It produces a small RNA
transcript lacking a poly-adenosine tail and has a well-defined
start of transcription as well as a termination signal. Cleavage of
the transcript after the second uridine of the termination signalwhich consists of five thymidines, yields a transcript resembling
the ends of a synthetic siRNA. The gene-specific insert is
designed as a 19-nucleotide sequence derived from the target
transcript, separated by a 9-nucleotide spacer from the reverse
complement of the same 19-nucleotide sequence. The resulting
transcript is predicted to fold back on itself to form a 19-base
pair stem–loop structure (Brummelkamp et al., 2002).
Three different sequences from the STAT3 gene were
inserted into the pSUPER vector and their functionality was
evaluated by transient transfections of 293T cells using a
plasmid encoding a FLAG-tagged STAT3 protein under the
control of the CMV promoter as target. Co-transfection of
shRNA (pSUPER) and an expression vector for the target RNA
(pRC-CMV-STAT3-FLAG) generates an equal distribution of
shRNA and target RNA in the cell and enables simple
monitoring of protein down-regulation. Targeting constitutively
expressed STAT3 might not allow the detection of a decrease in
STAT3 protein levels due to low transfection efficiencies of the
pSUPER plasmid. 293T cells were co-transfected with pRC-
CMV-STAT3-FLAG and one of the respective three pSUPER
plasmids in equal amounts. Forty-eight hours after the
transfections, the STAT3 (FLAG) protein amount was deter-
mined by Western blot analysis (Fig. 1A). The shRNA STAT 3–
3 (lane 4) showed the greatest effect on the target protein, as it
was almost undetectable in this setting. As control, we used the
pSUPER-EGFR plasmid, encoding an shRNA directed against
the EGFR mRNA, which had no effect on STAT3 protein levels
(lane 5). Equal protein loading was confirmed by incubating the
Fig. 3. Viral replication in transfected NIH3T3 cells monitored by the percentage
of GFP-positive cells. GFP-MOV, MLV with ecotropic Env carrying the GFP
sequence in the proline rich region; GFP-sh-STAT3-MOV, MLV with ecotropic
Env carrying the GFP sequence in the proline rich region and the siRNA
expression cassette at the env-3′ UTR boundary.
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was used for further cloning as it was most efficient in down-
regulating the STAT3 protein.
The same strategy was performed to test an shRNA against
EGFR. 293T cells were transfected with an EGFR expression
plasmid, either alone (Fig. 1B, lane 2) or with the shRNA-
encoding plasmids in equal amounts (lanes 1 and 3). Forty-eight
hours after transfection, the EGFR protein level was determined
by Western blot analysis (Fig. 1B). pSUPER-CD4 encodes an
shRNA directed against the human CD4-receptor and was used
as an unspecific control (lane 1). The target protein expression
could be specifically decreased by using the shEGFR plasmid
(lane 3). Detection of β-actin served as a loading control.
Transient transfections allowed the identification of two highly
efficient shRNAs directed against either the STAT3 or the
EGFR gene.
Construction and characterization of replication-competent
GFP-tagged MLVs carrying shRNA-expression cassettes
The major challenge for RNAi is still the adequate and
efficient delivery of shRNA in vivo. To overcome this problem,
we inserted the shRNA expression cassette into a replication-
competent MLV, which would distribute the shRNA while
replicating in the target cells.
We previously constructed a modified ecotropic Moloney
MLV (Mo-MLV) bearing the green fluorescent protein (GFP)
from Aequoria victoria in its envelope (Env), which enabled us
to visualize viral replication (GFP-MOV; Fig. 2) (Sliva et al.,
2004). Labeling Env with GFP did not change the specificity for
its receptor (Erlwein et al., 2003).
We inserted the sequence for the GFP-labeled Env into the
replication-competent pZAPm-GFP virus (kindly provided by
Noriyuki Kasahara; Los Angeles, USA). This modified MLV
carries unique restriction sites framing the IRES-GFP expres-
sion cassette at the env-3′ untranslated region (UTR) boundary
(Fig. 2). Logg et al. (2001) have demonstrated that an insertion
at this position is well tolerated as long as the insert size does not
exceed a certain threshold. We replaced the IRES-GFP
sequences with a sequence coding for the pol III promoter and
the sequences for shRNA (Fig. 2). The pol III expressionFig. 2. Generation of the GFP-Env-tagged viruses carrying the shRNA-expression cas
region; GFP, green fluorescent protein; L, signal peptide; shRNA, expression casse
ecotropicMo-MLV carrying an IRES-GFP expression cassette at the env-3′UTRboun
in the proline rich region. GFP-sh-STAT3-MOV: Modified ecotropic Mo-MLV bearin
cassette at the env-3′ UTR boundary. (For interpretation of the references to colour icassette with the corresponding shRNA sequence was excised
from the pSUPER plasmid with NotI andHindII and ligated into
the bluntedMluI site and sticky NotI sites of pZAPm-GFP. This
resulted in a reversed orientation of the shRNA-expression
cassette in the viral genome (Fig. 2). The insertion of GFP-
labeled Env enabled us to monitor viral replication via
distribution of GFP after elimination of the IRES-GFP sequence.
The recombinant viral genomes were transfected into
NIH3T3 cells and viral replication was quantified by fluores-
cence-activated cell sorter (FACS) analysis as the percentage of
GFP-positive cells in the culture. The cells were analyzed for
green fluorescence at different time points after transfection.
The inserted STAT3 shRNA expression cassettes did not
significantly interfere with viral fitness, as the viruses replicated
with similar kinetics as the parental GFP-MOV virus (Fig. 3).
Efficient down-regulation of target proteins in infected cells
To test whether virus replication distributes the shRNA-
expression-cassette functionally throughout the culture, wesette. Schematic representation of the GFP-Env-tagged viruses. PRR, proline rich
tte carrying siRNA driven by the pol III promoter H1. pZAPm-GFP: Modified
dary. GFP-MOV:Modified ecotropicMo-MLV bearing the GFP sequence in Env
g the GFP sequences in Env in the proline rich region and the shRNA-expression
n this figure legend, the reader is referred to the web version of this article.)
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in nearly 50% of human grade IV gliomas. The most
representative form of mutant EGFR involved in tumor
development is the EGFRvIII variant, which has been observed
in more than 25% of gliomas (Wikstrand et al., 1998; 1999) and
also in carcinomas of the lung, breast and prostate (Lorimer,
2002). The EGFR siRNA recognizes both EGFR and the
EGFRvIII variant. DHΔE cells, which are NIH3T3 cells stably
transfected with EGFRvIII (kindly provided from Winfried
Wels, Georg-Speyer-Haus, Frankfurt am Main, Germany), were
transfected with the viral genomes and cell lysates were
prepared after 5 days. Flow cytometry analysis revealed that
about 95% of the cells were infected (Fig. 4C). The level of the
target protein EGFRvIII was dramatically decreased in lysates
of cells infected with the MLV carrying the shRNA (Fig. 4A,
lane 2); however, they were not influenced by GFP-MOV
infection in the control (lane 1).
Similar observations were made using the virus carrying the
STAT3 shRNA, 37 days after transfection. In this case, a very
strong down-regulation of endogenously expressed STAT3
protein was observed in cell lysates of infected NIH3T3 cells
(Fig. 4B, lane 2).
The data show that the recombinant viruses are able to
replicate in vitro in the tissue cultured cells, distribute the
shRNAs and efficiently down-regulate the target proteins, even
after prolonged passage of the viruses.
Genomic stability of recombinant viruses
Replicating retrovirus populations are characterized by a
high degree of genetic change. However, an additional 1300
base pairs (bp) at the env-3′ UTR boundary in the MLV genomeFig. 4. Western blot analysis of whole cell lysates from cells infected with the modif
positive cells via FACS analysis (D, C). The results were comparable for viruses carry
with an antibody against EGFR. An antibody against β-actin was used as a control f
cells infected with GFP-sh-EGFR-MOV. (B) Infected 293Tcells analyzed with an anti
loading. Lane 1: uninfected 293T cells; Lane 2: 293T cells infected with GFP-sh-STwere stably integrated for over 8 infection cycles (Logg et al.,
2001). We therefore analyzed the genomic DNA for genetic
stability of the 360 bp shRNA expression cassette by
polymerase chain reaction (PCR) (Fig. 5). NIH3T3 cells were
transfected with the GFP-sh-STAT3-MOV genome. To assure
complete infection of the cells, viral supernatants were collected
9 days after transfection and 1 ml was applied onto fresh
NIH3T3 cells. This procedure was repeated for four consecutive
infection rounds. Long-term infected cells cultured for 43 days
were also analyzed as well (Fig. 5B, lane 6). Genomic DNAwas
isolated 9 days post transfection (lane 1) and after each of the
four infection rounds (lanes 2–5). The genomic stability of the
shRNA-expression cassettes was tested by PCR using primers
flanking the shRNA cassette (Fig. 5A). This generates a 529 bp
fragment from the GFP-sh-MOV genome and a 260 bp
fragment from the parental GFP-MOV genome, which lacks
this cassette (lane 7). As illustrated in Fig. 5B, the shRNA
expression cassette remained stably integrated in the genomic
DNA, as no other smaller bands, indicating deletions, could be
detected. Sequence analysis of the amplified DNA fragments
confirmed the sequence identity of the shRNA, thereby also
excluding shRNA inactivation by point mutations (Fig. 5C).
Discussion
The power of sh/siRNA in tumor therapy and for the
elucidation of gene function is without controversy in the
scientific world. However, the insufficient delivery of siRNA is
still the major obstacle. Retroviral vectors can be used to
express shRNA under the control of an RNA pol III promoter
(Brummelkamp et al., 2002; Rubinson et al., 2003), although
the relatively moderate amounts of viral particles producedied MLVs. The percentage of infected cells was determined by measuring GFP-
ing siRNAs against STAT3 and EGFR (D, C). (A) Infected DHΔE cells analyzed
or equal loading. Lane 1: DHΔE cells infected with GFP-MOV; Lane 2: DHΔE
body against STAT3. An antibody against β-actin was used as a control for equal
AT3-MOV.
Fig. 5. (A) Schematic representation of the primer design. (B) The genomic stability of the siRNA expression cassettes was analyzed by PCR of genomic DNA
(gDNA) using primers flanking the siRNA cassette. PCR of GFP-MOVand GFP-sh-STAT3-MOV generates 260 bp and 529 bp fragments, respectively. The gDNA
was isolated 9 days post-transfection, and after each of the four infection rounds. Lane 1: PCR of genomic DNA isolated 9 days post-transfection with GFP-sh-STAT3-
MOV; Lane 2: first infection round; Lane 3: second infection round; Lane 4: third infection round; Lane 5: fourth infection round; Lane 6: 43 days post-transfection;
Lane 7: PCR of parental plasmid GFP-MOV (wt). (C) The PCR fragments obtained as described above were sequenced using the 5′ flanking primer. The sequence of
the shRNA and the H1 promoter are indicated.
222 K. Sliva, B.S. Schnierle / Virology 351 (2006) 218–225(viral titer) are a major limitation, especially for cancer gene
therapy, which requires the transduction of a large amount of
cells.
To overcome problems due to poor transfection and
transduction efficiencies, we were interested to determine
whether a replication-competent retroviral vector containing
an expression cassette could distribute the shRNA among
mammalian cells. The presence of the shRNA stem–loop
structure could potentially interfere with the transcription of the
viral genome causing transcription termination. Alternatively,as the hairpin–structure represents dsRNA, the siRNA-
generating enzyme Dicer might be able to recognize the loop,
resulting in premature cleavage of the viral genomic RNA.
The MLVs used in our studies were tagged with a GFP-
containing envelope protein, which allowed a simple compar-
ison of the viral replication kinetics by flow cytometry. There
was no great difference between titers of MLVs containing an
shRNA expression cassette and those of the parental MLV
(GFP-MOV). This shows that the hairpin structure has no
obvious influence on transcription or premature cleavage. It is
223K. Sliva, B.S. Schnierle / Virology 351 (2006) 218–225possible that this takes place at an undetectable level but has no
apparent influence on the viral life cycle. It could be a question
of competition with the shRNA in that some of the viral
genomic RNA might be cleaved by Dicer, but the majority
translated without obstacle. In addition, we did not detect
interferon alpha secretion in supernatants of cells infected with
shRNA-encoding MLV (data not shown), confirming that small
dsRNAs do not induce interferon expression and unspecific
RNA degradation.
Successful integration of an shRNA expression cassette has
also been shown for Rous sarcoma virus (RSV); however, this
virus replicates only in avian cells and host defenses might
differ between avian and mammalian cells (Bromberg-White et
al., 2004). Unlike RSV, MLV has the ability to efficiently spread
the shRNA in mammalian cells and to be used for gene function
analysis.
Retroviruses are known to respond quickly to a new
environment by the selection of adapted variants. Therefore, it
is quite possible that sequences added to the MLV genome
become deleted. PCR analysis of cells infected with the shRNA-
containing MLVs was used to investigate the stability of the
expression cassette and clearly showed its stability in the MLV
genome even after four infection rounds. Logg et al. (2001)
previously showed that insertion of up to 1.3 kb of foreign
sequence at the env-3′ UTR boundary in the MLV genome was
well tolerated. Since the shRNA expression cassette only
accounts for 360 bp, it is very likely that these sequences are
relatively stable in the MLV genome, as their stem–loop nature
does not significantly interfere with the viral life cycle. It is
tempting to speculate that shRNAs interfering with genes
essential for viral fitness would be more prone to deletion.
Comparison between transfection with the pSUPER vectors
and infections with modified MLVs showed differences in the
effects of the shRNAs on their respective targets. While we
were never be able to down-regulate the endogenously
expressed STAT3 by transfection of NIH3T3 cells due to low
transfection efficiencies (data not shown), infection of the cells
with the shRNA-MLV directed against STAT3 shuts down
STAT3 protein synthesis to an undetectable level and shows the
power of the delivery system.
Cancer gene therapy based on replication-incompetent viral
vectors has been exploited over the last decade with less than
satisfactory results (Vile et al., 2000). Even direct in vivo
(intratumoral) administration of non-replicating retroviral and
adenoviral vectors – the two most widely used gene delivery
systems to date –mediated transgene expression in only a small
proportion (∼10%) of a solid tumor in each case (Ram et al.,
1997; Kruse et al., 1997). It is well documented that MLVs can
only replicate in actively dividing cells. Therefore, modified
replicating MLVs are excellent tools for efficient delivery of
shRNAs throughout the tumor tissue and have the potential to
be used to elucidate gene function or as vehicles for cancer gene
therapy. The further exploitation of our system could lead to a
perfect cancer therapy tool, since the use of replicating viruses
would solve the delivery problem and when combined with an
appropriate entry targeting strategy, delivery could be directed
exclusively to malignant cells.Materials and methods
Cell lines
NIH3T3 and 293T cells were grown in Dulbecco's modified
Eagle's medium (Invitrogen, Karlsruhe, Germany) supplemen-
ted with 10% fetal calf serum, 4 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin (Invitrogen, Karlsruhe,
Germany) at 37 °C in 10% CO2. NIH3T3-DHΔE 801-P cells
were cultured in the same medium with 1 mg/ml G418.
Plasmids
All plasmid constructions were carried out using standard
cloning procedures (Sambrook et al., 1989). Oligonucleo-
tides were purchased from MWG Biotech, Ebersberg,
Germany.
The following plasmids were used for transfections: pRC-
CMV-STAT3-FLAG encoding a FLAG-tagged STAT3 pro-
tein (kindly provided by Edith Pfitzner, Georg-Speyer-Haus,
Frankfurt am Main, Germany); pLTR-EGFR encoding the
human EGFR (kind gift of Winfried Wels, Georg-Speyer-
Haus, Frankfurt am Main, Germany); pGFP-MOV encoding
the ecotropic murine leukemia virus genome carrying the
GFP sequence in the proline-rich region of Env (Erlwein et
al., 2003; Sliva et al., 2004); pZAPm-GFP encoding the
complete genome of the ecotropic MLV carrying an IRES-
GFP expression cassette at the env-3′ UTR boundary
(kindly provided by Noriyuki Kasahara; Los Angeles, US)
(Logg et al., 2001); pSUPER-CD4 encoding the shRNA
expression cassette targeting the human CD4 receptor and
the pSUPER plasmids carrying the corresponding shRNAs
described later.
The pSUPER plasmids carrying the shRNAs against STAT3
were constructed using the following oligonucleotides.
pSUPER-STAT3-1
Forward primer:
5′-gatcccctgtcctctatcagcacaacttcaagagagttgtgctgatagaggacatttttggaaa
Reverse primer:
5′-agcttttccaaaaatgtcctctatcagcacaactctcttgaagttgtgctgatagaggacaggg
pSUPER-STAT3-2
Forward primer:
5′-gatccccaacatctgcctggaccgtcttcaagagagacggtccaggcagatgtttttggaaa
Reverse primer:
5′-agcttttccaaaaaaacatctgcctggaccgtctctcttgaagacggtccaggcagatgggg
pSUPER-STAT3-3
Forward primer:
5′-gatcccccttcagacccgccaacaaattcaagagatttgttgggcgggtctgaagtttttggaaa
Reverse primer:
5′-agcttttccaaaaacttcagacccgccaacaaatctcttgaatttgttgggcgggtctgaagggg
The sequence for an siRNA against EGFR was kindly
provided by Arjen Sloots and Winfried Wels (Georg-Speyer-
Haus, Frankfurt am Main, Germany) and can be obtained by
request.
The complementary oligonucleotides were annealed
(annealing buffer: 100 mM potassium acetate, 30 mM
HEPES-KOH pH 7.4, 2 mM Mg-acetate), phosphorylated
224 K. Sliva, B.S. Schnierle / Virology 351 (2006) 218–225and ligated into a BglII/HindIII digested pSUPER. Positive
clones were identified by restriction digestion and confirmed
by sequencing.
The complete pol III expression cassette with the
corresponding shRNA sequence was then excised from the
pSUPER plasmid with NotI and HindII and ligated into the
blunted MluI site and sticky NotI sites of pZAPm-GFP. This
resulted in a reversed orientation of the shRNA expression
cassette in the viral genome. The GFP-Env sequence was
introduced between HpaI restriction sites, replacing the wild
type Env sequence in the pZAPm-shRNA plasmid with that of
the GFP-Env-1 plasmid (Erlwein et al., 2003).
Transfections and infection assays
Plasmids encoding the shRNA sequences, the corresponding
target proteins or the MLV genomes were transfected using the
“FuGENE” reagent (Roche, Mannheim, Germany) according to
the manufacturer's instructions. NIH3T3 cells were seeded in 6
well plates at a density of 2 × 105 cell per well and transfected
using 2 μg plasmid DNA.
For infection assays, the viral supernatants were collected at
different time points after transfection, filtered through a
0.45 μm pore filter (Millipore, Eschborn, Germany) and 1 ml
was used per infection cycle to infect 2 × 105 cells.
Western blots
Cell lysates were obtained and Western blot analyses were
performed as described previously (Schnierle et al., 1996).
Western blot analysis was performed with the following
antibodies: polyclonal rabbit anti-EGFR antibody (sc-03)
(Santa Cruz Biotechnology; Heidelberg, Germany), mouse
anti-β-actin antibody (Sigma-Aldrich, Munich, Germany),
rabbit polyclonal anti-STAT3 antibody (sc-482) (Santa Cruz
Biotechnology, Heidelberg, Germany), mouse anti-FLAG M2
monoclonal antibody (Stratagene, Amsterdam, Netherlands),
sheep horseradish peroxidase-coupled anti-mouse IgG antibo-
dies and protein A (Amersham Biosciences, Freiburg, Ger-
many). Detection was performed using an enhanced
chemiluminescence detection kit (Amersham Biosciences,
Freiburg, Germany).
FACS analysis
GFP expression was monitored by a shift to green
fluorescence (FL-1). FACS analysis was performed with
FACScan (Becton Dickinson, Heidelberg; Germany) using the
Cellquest software.
PCR
Genomic DNA was isolated from infected cells using the
DNA tissue kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. Polymerase chain reaction (PCR)
was carried out using Taq polymerase (Roche, Mannheim,
Germany) according to the manufacturer's instructions. Thecycle used was 30 s at 94 °C, 30 s at 50 °C and 60 s at 72 °C.
The primers were p1 forward: 5′-cgattagtccaatttgtt-3′, priming
in the sense orientation at the 3′ end of env and p2 back: 5′-
gtcagcttgccaaacc-3′, priming in the antisense orientation at the
3′ LTR boundary. Oligonucleotides were purchased fromMWG
Biotech, Ebersberg, Germany.
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